| abstract |
There is provided a method of reversing resistance to a B-Raf inhibitor in the treatment of a proliferative disease by obtaining a tumor sample from the patient and testing it for genetic alterations in a panel of genes and using a drug combination therapy comprising the B-Raf inhibitor and a second inhibitor which overcomes resistance based on genetic alterations discovered in the tumor sample. In particular, there is provided a therapeutic combination of a compound of formula (1) and Compound B for treating a patient suffering from a proliferative disease characterized by a mutation in BRAF, wherein the patient exhibits a mechanism of disease progression characterized by a genetic alteration in BRAF, CRAP, MAP2K1, MAPK2, NRAS, KRAS, HRAS or EGFR, as detected in a tumor sample of said patient after said patient exhibited disease progression following therapy with a B-Raf inhibitor. (see formula I) (see Compound B) |